Retina/Vitreous News

SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Charles C. Wykoff, MD, PhD, discusses data from the GALE long-term extension study investigating Apellis Pharmaceuticals’ Syfovre for geographic atrophy.

SAN FRANCISCO — A one-time in-office injection of a gene therapy helped improve disease severity in patients with diabetic retinopathy.

SAN FRANCISCO — When administering anti-VEGF treatments to patients with wet age-related macular degeneration, diabetic macular edema or retinal vein occlusion who have severe glaucoma, be mindful of the speed and volume of injections.

The AMA has assigned a Category 1 CPT code for Xipere, according to a press release from Bausch + Lomb.

SAN FRANCISCO — It is important for ophthalmologists to understand FDA indications and develop a proper practice implementation strategy for new retinal drugs entering the market, according to a speaker here.

SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, George Magrath, MD, MBA, MS, CEO of Ocuphire Pharma, provides an update on APX3330 for the treatment of diabetic retinopathy.

Patients who experienced retinal artery occlusion are at higher risk for death, stroke and myocardial infarction in both the short and long term, according to a large retrospective cohort study.

In this Healio Video Perspective, David Almeida, MD, MBA, PhD, speaks about real-world study results of the fluocinolone acetonide intravitreal implant, a long-acting drug delivery system for diabetic macular edema.

SEATTLE — In this Healio Video Perspective from the ASRS meeting, Dilsher Dhoot, MD, discusses the interim results of the phase 2 ALTITUDE trial investigating three doses of RGX-314 gene therapy in diabetic retinopathy.

In this Healio Video Perspective, Ursula Schmidt-Erfurth, MD, speaks about OCT-based artificial intelligence analysis for the management of geographic atrophy, a topic she discussed at the Euretina congress in Amsterdam.